Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 272,60 CHF | +1,00% |
|
+1,83% | +6,69% |
| 11/06 | Amerikaanse FDA keurt longkankertherapie van Nuvation Bio goed | RE |
| 11/06 | Roche Canada meldt dat Health Canada PiaSky heeft goedgekeurd | RE |
Voorlopige winst- en verliesrekening: Roche Holding AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 58.323 | 62.801 | 63.281 | 58.716 | 60.495 | 63.169 | 65.900 | 68.021 |
| Variatie | - | 7,68% | 0,76% | -7,21% | 3,03% | 4,42% | 4,32% | 3,22% |
| EBITDA 1 | 24.281 | 24.692 | 25.015 | 21.976 | 23.538 | 25.440 | 26.407 | 27.668 |
| Variatie | - | 1,69% | 1,31% | -12,15% | 7,11% | 8,08% | 3,8% | 4,78% |
| Bedrijfsresultaat (EBIT) 1 | 21.536 | 21.897 | 22.173 | 19.240 | 20.823 | 22.185 | 23.286 | 24.500 |
| Variatie | - | 1,68% | 1,26% | -13,23% | 8,23% | 6,54% | 4,96% | 5,22% |
| Betaalde rente 1 | -578 | -757 | -1.214 | -1.300 | -1.610 | -1.260 | -1.212 | -1.146 |
| Resultaat voor belastingen (EBT) 1 | 17.965 | 17.398 | 16.327 | 14.079 | 11.793 | 19.465 | 21.013 | 22.489 |
| Variatie | - | -3,16% | -6,16% | -13,77% | -16,24% | 65,06% | 7,95% | 7,02% |
| Nettowinst (verlies) 1 | 14.295 | 13.930 | 12.421 | 11.498 | 8.277 | 14.067 | 15.214 | 16.245 |
| Variatie | - | -2,55% | -10,83% | -7,43% | -28,01% | 69,96% | 8,15% | 6,78% |
| Datum van publicatie | 4/02/21 | 3/02/22 | 2/02/23 | 1/02/24 | 30/01/25 | - | - | - |
1CHF in Miljoen
Geschatte gegevens
Balansprognose: Roche Holding AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | 1.882 | 18.167 | 15.584 | 18.699 | 17.337 | 11.291 | 5.732 | -2.719 |
| Variatie | - | 865,3% | -14,22% | 19,99% | -7,28% | -34,87% | -49,23% | -147,44% |
| Datum van publicatie | 4/02/21 | 3/02/22 | 2/02/23 | 1/02/24 | 30/01/25 | - | - | - |
1CHF in Miljoen
Geschatte gegevens
Verwachte kasstroom: Roche Holding AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 3.528 | 3.693 | 3.449 | 3.742 | 3.529 | 3.935 | 4.078 | 4.201 |
| Variatie | - | 4,68% | -6,61% | 8,5% | -5,69% | 11,5% | 3,65% | 3,01% |
| Vrije kasstroom (FCF) 1 | 10.943 | 15.691 | 13.041 | 11.288 | 15.336 | 15.011 | 16.188 | 16.881 |
| Variatie | - | 43,39% | -16,89% | -13,44% | 35,86% | -2,12% | 7,84% | 4,28% |
| Datum van publicatie | 4/02/21 | 3/02/22 | 2/02/23 | 1/02/24 | 30/01/25 | - | - | - |
1CHF in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: Roche Holding AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | 41,63% | 39,32% | 39,53% | 37,43% | 38,91% | 40,27% | 40,07% | 40,68% |
| EBIT-marge (%) | 36,93% | 34,87% | 35,04% | 32,77% | 34,42% | 35,12% | 35,33% | 36,02% |
| EBT-marge (%) | 30,8% | 27,7% | 25,8% | 23,98% | 19,49% | 30,81% | 31,89% | 33,06% |
| Nettomarge (%) | 24,51% | 22,18% | 19,63% | 19,58% | 13,68% | 22,27% | 23,09% | 23,88% |
| FCF-marge (%) | 18,76% | 24,99% | 20,61% | 19,22% | 25,35% | 23,76% | 24,56% | 24,82% |
| Vrije kasstroom/nettoresultaat (%) | 76,55% | 112,64% | 104,99% | 98,17% | 185,28% | 106,71% | 106,4% | 103,92% |
Winstgevendheid | ||||||||
| ROA | 19,59% | 19,09% | 18,18% | 16,71% | 15,69% | 14,17% | 14,14% | 13,81% |
| ROE | 47,99% | 56,02% | 62,5% | 45,73% | 43,45% | 44,32% | 39,38% | 35,4% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | 0,08x | 0,74x | 0,62x | 0,85x | 0,74x | 0,44x | 0,22x | - |
| Schuld/vrije kasstroom | 0,17x | 1,16x | 1,2x | 1,66x | 1,13x | 0,75x | 0,35x | - |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 6,05% | 5,88% | 5,45% | 6,37% | 5,83% | 6,23% | 6,19% | 6,18% |
| CAPEX / EBITDA (%) | 14,53% | 14,96% | 13,79% | 17,03% | 14,99% | 15,47% | 15,44% | 15,18% |
| CAPEX / FCF (%) | 32,24% | 23,54% | 26,45% | 33,15% | 23,01% | 26,21% | 25,19% | 24,89% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | 21,46 | 24,39 | 22,79 | 20,02 | 25,05 | 23,4 | 25,21 | 27,32 |
| Variatie | - | 13,64% | -6,56% | -12,16% | 25,16% | -6,62% | 7,77% | 8,35% |
| Dividend per aandeel 1 | 9,1 | 9,3 | 9,5 | 9,6 | 9,7 | 9,879 | 10,14 | 10,4 |
| Variatie | - | 2,2% | 2,15% | 1,05% | 1,04% | 1,84% | 2,6% | 2,58% |
| Nettoactief per aandeel 1 | 42,5 | 28,81 | 35,03 | 41,37 | 45,09 | 48,57 | 57,98 | 67,68 |
| Variatie | - | -32,22% | 21,58% | 18,12% | 8,98% | 7,72% | 19,37% | 16,74% |
| WPA 1 | 16,52 | 16,2 | 15,37 | 14,31 | 10,31 | 18,27 | 19,8 | 21,22 |
| Variatie | - | -1,94% | -5,12% | -6,9% | -27,95% | 77,21% | 8,35% | 7,18% |
| Aantal aandelen (in duizend) | 854.642 | 800.952 | 854.579 | 798.652 | 796.789 | 795.401 | 795.401 | 795.401 |
| Datum van publicatie | 4/02/21 | 3/02/22 | 2/02/23 | 1/02/24 | 30/01/25 | - | - | - |
1CHF
Geschatte gegevens
| 2025 * | 2026 * | |
|---|---|---|
| k/w-verhouding | 14,9x | 13,8x |
| PBR-ratio | 5,61x | 4,7x |
| EV/omzet | 3,64x | 3,41x |
| Dividendrendement | 3,62% | 3,72% |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Verkoop
Koop
Gemiddeld advies
Houden
Aantal analisten
20
Laatste slotkoers
272,60CHF
Gemiddelde koersdoel
302,63CHF
Spread / Gemiddelde doel
+11,02%
Kwartaalomzet - Afwijkingspercentage
Kies jouw editie
Alle financiële informatie op nationaal niveau
